Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 750 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Benralizumab 10 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Benralizumab 30 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Benralizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · men (ages > 18 years) with clinically localized prostate cancer
It is very uncertain whether retzius‐sparing RALP changes serious adverse events compared with standard RALP (very low certainty).
1 finding from 1 review
Serious adverse events · Children and older adults treated with SDF for carious lesions
No serious adverse events (e.g., allergic reactions or toxicity) were reported for SDF across the reviews (ungraded).
1 finding from 1 review
Adverse events: nausea · heavy menstrual bleeding
Combined oral contraceptive pill may leads to higher adverse events: nausea compared with contraceptive vaginal ring (low certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Alteplase may leads to higher serious adverse events compared with urokinase (low certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Fibrinolytics showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Streptokinase showed no clear difference in serious adverse events compared with urokinase (low certainty).
1 finding from 1 review
Serious adverse events · advanced hormone‐sensitive prostate cancer
Early showed no clear difference in serious adverse events compared with deferred AST (low certainty).
1 finding from 1 review
Serious adverse events · cirrhotic participants with large ascites treated by paracentesis
1 finding from 1 review
Serious adverse events · cirrhotic participants with large ascites treated by paracentesis
It is very uncertain whether other plasma expanders changes serious adverse events compared with albumin (very low certainty).
1 finding from 1 review
Adverse event: tremor · acute mania
Lithium showed no clear difference in adverse events: tremor compared with aripiprazole (moderate certainty).
1 finding from 1 review
Serious adverse events · people with impingement syndrome without full‐thickness rotator cuff tears
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Serious adverse events · people with impingement syndrome without full‐thickness rotator cuff tears
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found